http://www.drugs.com/pro/forteo.htmlIndications and Usage for Forteo
Forteo is indicated for the treatment of postmenopausal women with osteoporosis who are at high risk for fracture. These include women with a history of osteoporotic fracture, or who have multiple risk factors for fracture, or who have failed or are intolerant of previous osteoporosis therapy, based upon physician assessment (see BLACK BOX WARNING). In postmenopausal women with osteoporosis, Forteo increases BMD and reduces the risk of vertebral and nonvertebral fractures.
Forteo is indicated to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. These include men with a history of osteoporotic fracture, or who have multiple risk factors for fracture, or who have failed or are intolerant to previous osteoporosis therapy, based upon physician assessment (see BLACK BOX WARNING). In men with primary or hypogonadal osteoporosis, Forteo increases BMD. The effects of Forteo on risk for fracture in men have not been studied.
Forteo reduces the risk of vertebral fractures in postmenopausal women with osteoporosis.
Forteo reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis.
Forteo increases vertebral and femoral neck BMD in postmenopausal women with osteoporosis and in men with primary or hypogonadal osteoporosis.
The effects of Forteo on fracture risk have not been studied in men.